Goh M et al., 2025-07-02: The most recent analysis of US neglected-tropical-disease drug pricing finds mebendazole went from $4.93 per pill (Vermox, discontinued 2011) to $423.39 per pill when Emverm launched in 2016, rising 60% to $678.80 by 2024, while albendazole fell 78% over 2019-2024. It documents both the scale of the mebendazole price increase and its persistence to 2024.
Mebendazole's weighted average price per pill rose over time. The Vermox formulation of mebendazole was priced at $4.93 per pill but discontinued in 2011. Another brand-name version, Emverm, entered the US market in 2016, starting at $423.39 per pill, which increased by 60% to $678.80 by 2024.
Results
Goh M et al., 2025-07-02: The most recent analysis of US neglected-tropical-disease drug pricing finds mebendazole went from $4.93 per pill (Vermox, discontinued 2011) to $423.39 per pill when Emverm launched in 2016, rising 60% to $678.80 by 2024, while albendazole fell 78% over 2019-2024. It documents both the scale of the mebendazole price increase and its persistence to 2024. Study type: retrospective price and supply analysis of 11 NTD products, 2019-2024 (with historical context back to 2011). Country: United States. N/A (product-level). Data sources named: Symphony Metys, First Databank, NAVLIN, Red Book, University of Utah Drug Information Service. Funding: 'This work was supported by Arnold Ventures.' Conflicts: 'A. S. K.' (Kesselheim) 'reports serving as an expert witness on behalf of a class of state attorneys general and payers related to alleged generic drug price fixing'; other authors report none. The paper also gives a treatment course of 5-6 mebendazole pills. NOTE a discrepancy with FDA records: this paper says Vermox was 'discontinued in 2011', consistent with Teva's exit (MBA-20) but not with Janssen's later 500 mg NDA 208398 approval in 2016 (MBA-09) – see flag report. Study type: other.
